

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.



Summary of Financial Statements for the Six Months Ended September 30, 2022 [IFRS] (Consolidated)



November 4, 2022

Company name: JMDC Inc.
 Listing: Tokyo Stock Exchange
 Stock code: 4483
 URL: <https://www.jmdc.co.jp/en/>
 Representative: Yosuke Matsushima, President and CEO
 Inquiries: Yuta Yamamoto, Vice President and CFO
 TEL: +81-3-5733-5010
 Scheduled date to file quarterly securities report: November 11, 2022
 Scheduled date to commence dividend payments: —
 Preparation of supplementary material on quarterly financial results: Yes
 Holding of quarterly financial results presentation meeting: Yes (for institutional investors and analysts)

(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Consolidated financial results for the first six months of the fiscal year ending March 31, 2023 (from April 1, 2022 to September 30, 2022)

(1) Consolidated operating results (cumulative) (Percentages indicate year-on-year changes.)

	Revenue		Operating profit		Profit before tax		Profit	
Six months ended	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
September 30, 2022	12,060	26.3	2,207	27.4	2,234	30.3	1,436	26.4
September 30, 2021	9,550	36.9	1,733	56.5	1,715	55.8	1,137	56.0

	Profit attributable to owners of parent		Total comprehensive income		Basic earnings per share	Diluted earnings per share
Six months ended	Millions of yen	%	Millions of yen	%	Yen	Yen
September 30, 2022	1,444	27.0	1,442	26.9	25.29	23.86
September 30, 2021	1,136	55.8	1,136	55.8	20.26	19.06

Reference: EBITDA Six months ended September 30, 2022 ¥2,956 million [19.6%]

Six months ended September 30, 2021 ¥2,472 million [48.6%]

Notes: 1. EBITDA: Operating profit + Depreciation and amortization ± Other income and/or expenses

2. During the six months ended September 30, 2022, the Company finalized the provisional accounting treatment for business combinations. As a result, figures for the six months ended September 30, 2021 reflect the finalization of the provisional accounting treatment.

(2) Consolidated financial position

	Total assets	Total equity	Equity attributable to owners of parent	Ratio of equity attributable to owners of parent
As of	Millions of yen	Millions of yen	Millions of yen	%
September 30, 2022	112,092	61,610	61,638	55.0
March 31, 2022	62,053	31,165	31,170	50.2

Note: During the six months ended September 30, 2022, the Company finalized the provisional accounting treatment for business combinations. As a result, figures as of March 31, 2022 reflect the finalization of the provisional accounting treatment.

2. Cash dividends

	Annual dividends				
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended March 31, 2022	—	0.00	—	10.00	10.00
Fiscal year ending March 31, 2023	—	0.00			
Fiscal year ending March 31, 2023 (Forecast)			—	—	—

Note: Revisions to the forecast of cash dividends most recently announced: None

3. Consolidated earnings forecasts for the fiscal year ending March 31, 2023 (from April 1, 2022 to March 31, 2023)

(Percentages indicate year-on-year changes.)

	Revenue		Operating profit		Profit before tax		Profit		Profit attributable to owners of parent		Basic earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	
Fiscal year ending March 31, 2023	27,500	26.1	6,000	25.4	6,000	25.8	4,000	23.4	4,000	23.2	Yen 69.73

Note: Revisions to the earnings forecasts most recently announced: None

Reference: EBITDA Fiscal year ending March 31, 2023

¥8,000 million [24.8%]

*** Notes**

- (1) Changes in significant subsidiaries during the period (changes in specified subsidiaries resulting in the change in scope of consolidation): None

Added companies: - (company name), Excluded companies: - (company name)

- (2) Changes in accounting policies and changes in accounting estimates

(i) Changes in accounting policies required by IFRS: None

(ii) Changes in accounting policies due to other reasons: None

(iii) Changes in accounting estimates: None

- (3) Number of issued shares (ordinary shares)

- (i) Total number of issued shares at end of the period (including treasury shares)

As of September 30, 2022	62,761,808 shares
As of March 31, 2022	56,514,208 shares

- (ii) Number of treasury shares at end of the period

As of September 30, 2022	529 shares
As of March 31, 2022	497 shares

- (iii) Average number of shares outstanding during the period (cumulative from the beginning of the fiscal year)

For the six months ended September 30, 2022	57,114,128 shares
For the six months ended September 30, 2021	56,086,431 shares

- * Quarterly financial results reports are exempt from quarterly reviews conducted by certified public accountants or an audit corporation.**

- * Proper use of earnings forecasts, and other special items**

Notes on forward-looking statements

The forward-looking statements, including earnings forecasts, contained in these materials are based on information currently available to the Company and on certain assumptions deemed to be reasonable by the Company. Actual business and other results may differ substantially due to various factors. For details regarding matters related to earnings forecasts, please refer to page 5 of the attached materials.

How to obtain supplementary documents on financial results

Supplementary documents on financial results are released via TDnet on the same day.

Attached Material Index

1. Qualitative information regarding financial results for the six months ended September 30, 2022	2
(1) Explanation of operating results	2
(2) Explanation of financial position.....	4
(3) Explanation of consolidated earnings forecasts and other forward-looking statements.....	5
2. Condensed quarterly consolidated financial statements and significant notes thereto	6
(1) Condensed quarterly consolidated statement of financial position	6
(2) Condensed quarterly consolidated statement of profit or loss and condensed quarterly consolidated statement of comprehensive income	7
(3) Condensed quarterly consolidated statement of changes in equity	9
(4) Condensed quarterly consolidated statement of cash flows	11
(5) Notes to condensed quarterly consolidated financial statements.....	12
Notes on going concern assumption.....	12
Segment information	12
Significant subsequent events.....	13

1. Qualitative information regarding financial results for the six months ended September 30, 2022

(1) Explanation of operating results

JMDC Inc. (the “Company”) is promoting the health of citizens, and delivering increased value of medical service providers and helping optimize their operations through gathering diverse data on the Japanese healthcare industry and thus benefiting society, with the aim of realizing a sustainable healthcare system by leveraging data and ICT.

In the Healthcare-Big Data segment, to promote the health services for payers, centered on health insurance associations, we provide analysis services for data held by payers as well as personal health record (PHR) services developed by the Company. We also provide services such as medical data analysis and medical factoring to medical institutions as well as medicine databases. Furthermore, we have created a database of anonymously processed information in the course of pursuing this business and are promoting scientific and industrial applications of this data.

In the Tele-medicine segment, we provide a matching service that connects medical institutions lacking a sufficient number of radiologists with contracted radiologists using a remote image interpretation system, as well as an ASP service that connects medical institutions with radiologists via the cloud to enable remote diagnostic imaging.

In the Dispensing Pharmacy Support segment, we develop and sell systems such as receipt computers and electronic medication history systems to health insurance pharmacies, and also conduct tests of our own systems as we operate our own dispensing pharmacies.

Operating results for the six months ended September 30, 2022 are as follows.

(Operating results)

(Millions of yen)

Category	9th fiscal year Six months ended September 30, 2021	10th fiscal year Six months ended September 30, 2022	YoY change	
Revenue	9,550	12,060	2,509	26.3%
Operating profit	1,733	2,207	474	27.4%
EBITDA [Margin]	2,472 [25.9%]	2,956 [24.5%]	483	19.6%

(Segment results)

(Millions of yen)

Category		9th fiscal year Six months ended September 30, 2021	10th fiscal year Six months ended September 30, 2022	YoY change	
Healthcare-Big Data	Segment revenue	5,829	7,903	2,073	35.6%
	Segment profit [ratio]	1,735 [29.8%]	2,028 [25.7%]	292	16.9%
Tele-medicine	Segment revenue	2,149	2,439	290	13.5%
	Segment profit [ratio]	730 [34.0%]	924 [37.9%]	194	26.6%
Dispensing Pharmacy Support	Segment revenue	1,659	1,843	184	11.1%
	Segment profit [ratio]	163 [9.8%]	192 [10.5%]	29	17.9%
Adjustment	Segment revenue	(88)	(126)	(37)	—
	Segment profit	(157)	(189)	(32)	—
Total	Revenue	9,550	12,060	2,509	26.3%
	EBITDA [margin]	2,472 [25.9%]	2,956 [24.5%]	483	19.6%

(Note) EBITDA is an objective indicator for judging the achievement of the JMDC Group's (the “Group's”) management policies and strategies or management objectives. The Group uses EBITDA to measure the performance of each segment and believes that it is a useful and necessary measure to assess the Group's performance more effectively. The formulas for calculating EBITDA and EBITDA margin are as follows.

- EBITDA: Operating profit + Depreciation and amortization ± Other income and/or expenses
- EBITDA margin: EBITDA / Revenue x 100

In the six months ended September 30, 2022, the Company conducted issuance of new shares through an international offering and issuance of new shares through third-party allotment for OMRON

Corporation, and recorded ¥29,212 million in proceeds from issuance of shares. This is in order to secure financial reserve to continuously and flexibly develop new business and carry out M&As with the aim of capturing extensive business opportunities in the field of healthcare-big data. The Company plans to use the procured funds for: (i) repayments of borrowings borrowed from financial institutions with the aim of allocation to the latest M&As; (ii) allocation to cash and deposits decreased as a result of allocation of funds in hand for past M&As; and (iii) allocation to a part of funds for capital investment for the expansion of business activities.

Results by each segment are as follows.

Healthcare-Big Data

During the six months ended September 30, 2022, various negative factors such as the curtailment of face-to-face sales due to the spread of the novel coronavirus disease (COVID-19) continued. However, the business continued to expand.

The number of contracted health insurance associations, the number of IDs issued for the Pep Up health information platform developed by the Company, and the annual transaction value per customer at pharmaceutical and insurance companies all continued to increase on a year-on-year basis.

In the six months ended September 30, 2022, the Company significantly expanded its data originating from medical institutions by making Real World Data Co., Ltd. and other companies its subsidiaries, and started initiatives to provide services in new areas such as clinical trials, etc.

At the same time, in order to capture rapidly expanding business opportunities and accelerate future growth through expanding data volume and data types and increasing services and solutions, we continue to make proactive up-front investments focused on personnel.

As a result, segment revenue for the six months ended September 30, 2022 was ¥7,903 million and segment profit (segment EBITDA) was ¥2,028 million.

Tele-medicine

During the six months ended September 30, 2022, although the impact of a decrease in diagnostic imaging requests per medical institution due to the voluntary refraining from visiting hospitals as a result of the spread of COVID-19 continued, there were signs of recovery year on year, and revenue increased on a year-on-year basis as a result of the increase in the number of medical institutions utilizing remote image interpretation services. As a result of the business expansion, the number of radiologists contracted by the Group exceeded 1,000 in the six months ended September 30, 2022, which consolidates our position as the biggest platform for radiologists in Japan.

We continue to take measures to expand our business, including adding functions to “AI-RAD,” an artificial intelligence engine platform that assists in diagnostic imaging, and preparations for full-scale business development in China.

As a result, segment revenue for the six months ended September 30, 2022 was ¥2,439 million and segment profit (segment EBITDA) was ¥924 million.

Dispensing Pharmacy Support

During the six months ended September 30, 2022, we worked to cultivate new customers while securing replacement demand from existing customers. Although the Group continued to be affected by a decline in sales at its own dispensing pharmacies and investment constraints at client dispensing pharmacies due to people refraining from visiting medical agencies, which will in turn reduce the number of times they visit dispensing pharmacies as a result of the spread of COVID-19, sales increased on a year-on-year basis affected by the addition of a former competitor to the Group during the first quarter of the previous fiscal year.

As a result, segment revenue for the six months ended September 30, 2022 was ¥1,843 million and segment profit (segment EBITDA) was ¥192 million.

As a result of the above, for the six months ended September 30, 2022, revenue increased to ¥12,060 million, operating profit to ¥2,207 million, and EBITDA to ¥2,956 million. Adjustments to reconcile EBITDA to operating profit are as follows.

(Reconciliation of EBITDA to operating profit)

	9th fiscal year Six months ended September 30, 2021	10th fiscal year Six months ended September 30, 2022
EBITDA	2,472	2,956
Depreciation and amortization	(750)	(936)
Other income	33	203
Other expenses	(21)	(14)
Operating profit	1,733	2,207

(Millions of yen)

(2) Explanation of financial position

(i) Assets, liabilities and equity

Assets

Assets at the end of the second quarter under review were ¥112,092 million, an increase of ¥50,039 million compared with the end of the fiscal year ended March 31, 2022. This was primarily due to an increase of ¥28,274 million in cash and cash equivalents as a result of the issuance of new shares through an international offering and the issuance of new shares through third-party allotment for OMRON Corporation, in addition to an increase of ¥19,709 million in goodwill due to the acquisition of the shares of Real World Data Co., Ltd. (subsidiary acquisition), etc.

Liabilities

Liabilities at the end of the second quarter under review were ¥50,482 million, an increase of ¥19,594 million compared with the end of the fiscal year ended March 31, 2022. This was primarily due to an increase of ¥19,497 million in borrowings under current liabilities as a result of borrowing funds to purchase multiple shares, some of which had already been paid for.

Equity

Equity at the end of the second quarter under review was ¥61,610 million, an increase of ¥30,444 million compared with the end of the fiscal year ended March 31, 2022. This was primarily due to an increase of ¥885 million in retained earnings due to the recording of ¥1,444 million in profit, ¥565 million in dividends paid, etc., in addition to increases of ¥14,872 million and ¥14,698 million in share capital and capital surplus, respectively, as a result of the issuance of new shares through an international offering and the issuance of new shares through third-party allotment for OMRON Corporation, etc.

(ii) Cash flows

Cash and cash equivalents (“cash”) at the end of the second quarter under review was ¥41,467 million, an increase of ¥28,273 million compared with the end of the fiscal year ended March 31, 2022.

The respective cash flow positions for the six months ended September 30, 2022, and the factors thereof are as follows.

Cash flows from operating activities

During the six months ended September 30, 2022, profit before tax was ¥2,234 million, an increase of ¥518 million on a year-on-year basis. Other inflows included depreciation and amortization of ¥936 million. At the same time, there were outflows of ¥1,244 million from a decrease in trade and

other payables and ¥1,029 million from recording income taxes paid. As a result, net cash provided by operating activities was ¥1,682 million.

Cash flows from investing activities

Net cash used in investing activities was ¥21,494 million. This was primarily due to purchase of shares of subsidiaries resulting in change in scope of consolidation of ¥19,202 million and purchase of property, plant and equipment of ¥1,147 million.

Cash flows from financing activities

Net cash provided by financing activities was ¥48,086 million. This was primarily due to the recording of ¥19,330 million in proceeds from short-term borrowings of funds to purchase multiple shares, some of which had already been paid for, and the recording of ¥29,212 million in proceeds from issuance of shares as a result of the issuance of new shares through an international offering and the issuance of new shares through third-party allotment for OMRON Corporation, despite the recording of ¥564 million in dividends paid.

(3) Explanation of consolidated earnings forecasts and other forward-looking statements

As for the consolidated earnings forecasts, although the impact of the spread of COVID-19 continues to be unpredictable, the Company believes that the impact on the Group will not deviate significantly from the initial forecast at this time. Furthermore, as at this point in time it is not possible to perform a reasonable calculation of the impact on operating results of making Real World Data Co., Ltd. a subsidiary of the Company and other factors. As a result, there is no change to the consolidated earnings forecasts stated in the “Summary of Financial Statements for the Fiscal Year Ended March 31, 2022” released on May 10, 2022.

2. Condensed quarterly consolidated financial statements and significant notes thereto

(1) Condensed quarterly consolidated statement of financial position

(Millions of yen)

	As of March 31, 2022	As of September 30, 2022
Assets		
Current assets		
Cash and cash equivalents	13,192	41,467
Trade and other receivables	9,283	9,054
Other financial assets	2,561	3,127
Inventories	248	291
Other current assets	693	650
Total current assets	25,979	54,590
Non-current assets		
Property, plant and equipment	8,420	9,447
Goodwill	19,169	38,878
Intangible assets	5,527	5,779
Other financial assets	1,298	1,654
Deferred tax assets	1,516	1,577
Other non-current assets	141	164
Total non-current assets	36,073	57,502
Total assets	62,053	112,092
Liabilities and equity		
Liabilities		
Current liabilities		
Borrowings	777	20,274
Trade and other payables	6,182	5,174
Lease liabilities	689	780
Income taxes payable	999	745
Contract liabilities	1,843	2,121
Other current liabilities	1,140	998
Total current liabilities	11,633	30,095
Non-current liabilities		
Borrowings	10,928	11,826
Lease liabilities	5,401	5,534
Retirement benefit liability	319	338
Provisions	276	451
Deferred tax liabilities	769	755
Contract liabilities	1,560	1,481
Total non-current liabilities	19,254	20,387
Total liabilities	30,887	50,482
Equity		
Share capital	9,091	23,964
Capital surplus	12,483	27,182
Treasury shares	(2)	(2)
Other components of equity	17	27
Retained earnings	9,580	10,466
Total equity attributable to owners of parent	31,170	61,638
Non-controlling interests	(5)	(28)
Total equity	31,165	61,610
Total liabilities and equity	62,053	112,092

(2) Condensed quarterly consolidated statement of profit or loss and condensed quarterly consolidated statement of comprehensive income

Condensed quarterly consolidated statement of profit or loss

(Millions of yen)

	Six months ended September 30, 2021	Six months ended September 30, 2022
Revenue	9,550	12,060
Cost of sales	4,263	5,342
Gross profit	5,287	6,717
Selling, general and administrative expenses	3,565	4,697
Other income	33	203
Other expenses	21	14
Operating profit	1,733	2,207
Finance income	13	68
Finance costs	31	42
Profit before tax	1,715	2,234
Income tax expense	578	797
Profit	1,137	1,436
Profit attributable to		
Owners of parent	1,136	1,444
Non-controlling interests	0	(7)
Profit	1,137	1,436
Earnings per share		
Basic earnings per share (Yen)	20.26	25.29
Diluted earnings per share (Yen)	19.06	23.86

Condensed quarterly consolidated statement of comprehensive income

(Millions of yen)

	Six months ended September 30, 2021	Six months ended September 30, 2022
Profit	1,137	1,436
Other comprehensive income		
Items that will not be reclassified to profit or loss		
Financial assets measured at fair value through other comprehensive income	0	6
Total of items that will not be reclassified to profit or loss	0	6
Items that may be reclassified to profit or loss		
Foreign exchange differences on translation of foreign operations	(0)	(1)
Total of items that may be reclassified to profit or loss	(0)	(1)
Other comprehensive income, net of tax	(0)	5
Comprehensive income	1,136	1,442
Comprehensive income attributable to		
Owners of parent	1,136	1,449
Non-controlling interests	0	(7)
Comprehensive income	1,136	1,442

(3) Condensed quarterly consolidated statement of changes in equity

Six months ended September 30, 2021 (from April 1 to September 30, 2021)

(Millions of yen)

	Equity attributable to owners of parent					
	Share capital	Capital surplus	Treasury shares	Other components of equity		
				Exchange differences on translation of foreign operations	Financial assets measured at fair value through other comprehensive income	Share acquisition rights
Balance as of April 1, 2021	8,971	12,932	(1)	(2)	—	25
Profit	—	—	—	—	—	—
Other comprehensive income	—	—	—	(0)	0	—
Total comprehensive income	—	—	—	(0)	0	—
Issuance of share acquisition rights	—	—	—	—	—	1
Share-based remuneration transactions	—	—	—	—	—	0
Exercise of share acquisition rights	60	51	—	—	—	(3)
Forfeiture of share acquisition rights	—	0	—	—	—	(0)
Purchase of treasury shares	—	—	(0)	—	—	—
Increase (decrease) by business combination	—	(560)	—	—	—	—
Transfer to retained earnings	—	—	—	—	(0)	—
Total transactions with owners	60	(509)	(0)	—	(0)	(1)
Balance as of September 30, 2021	9,032	12,423	(1)	(2)	—	24

	Equity attributable to owners of parent				
	Other components of equity	Retained earnings	Total	Non-controlling interests	Total
	Total				
Balance as of April 1, 2021	23	6,323	28,250	—	28,250
Profit	—	1,136	1,136	0	1,137
Other comprehensive income	(0)	—	(0)	—	(0)
Total comprehensive income	(0)	1,136	1,136	0	1,136
Issuance of share acquisition rights	1	—	1	—	1
Share-based remuneration transactions	0	—	0	—	0
Exercise of share acquisition rights	(3)	—	108	—	108
Forfeiture of share acquisition rights	(0)	—	—	—	—
Purchase of treasury shares	—	—	(0)	—	(0)
Increase (decrease) by business combination	—	—	(560)	0	(559)
Transfer to retained earnings	(0)	0	—	—	—
Total transactions with owners	(1)	0	(451)	0	(450)
Balance as of September 30, 2021	21	7,460	28,935	0	28,936

Six months ended September 30, 2022 (from April 1 to September 30, 2022)

(Millions of yen)

	Equity attributable to owners of parent					
	Share capital	Capital surplus	Treasury shares	Other components of equity		
				Exchange differences on translation of foreign operations	Financial assets measured at fair value through other comprehensive income	Share acquisition rights
Balance as of April 1, 2022	9,091	12,483	(2)	(4)	—	21
Profit	—	—	—	—	—	—
Other comprehensive income	—	—	—	(1)	6	—
Total comprehensive income	—	—	—	(1)	6	—
Issuance of share acquisition rights	—	—	—	—	—	13
Exercise of share acquisition rights	140	140	—	—	—	(1)
Forfeiture of share acquisition rights	—	0	—	—	—	(0)
Issuance of new shares	14,732	14,558	—	—	—	—
Purchase of treasury shares	—	—	(0)	—	—	—
Dividends	—	—	—	—	—	—
Increase (decrease) by business combination	—	—	—	—	—	—
Transfer to retained earnings	—	—	—	—	(6)	—
Total transactions with owners	14,872	14,698	(0)	—	(6)	11
Balance as of September 30, 2022	23,964	27,182	(2)	(5)	—	33

	Equity attributable to owners of parent				
	Other components of equity	Retained earnings	Total	Non-controlling interests	Total
	Total				
Balance as of April 1, 2022	17	9,580	31,170	(5)	31,165
Profit	—	1,444	1,444	(7)	1,436
Other comprehensive income	5	—	5	—	5
Total comprehensive income	5	1,444	1,449	(7)	1,442
Issuance of share acquisition rights	13	—	13	—	13
Exercise of share acquisition rights	(1)	—	279	—	279
Forfeiture of share acquisition rights	(0)	—	—	—	—
Issuance of new shares	—	—	29,290	—	29,290
Purchase of treasury shares	—	—	(0)	—	(0)
Dividends	—	(565)	(565)	—	(565)
Increase (decrease) by business combination	—	—	—	(15)	(15)
Transfer to retained earnings	(6)	6	—	—	—
Total transactions with owners	4	(558)	29,018	(15)	29,002
Balance as of September 30, 2022	27	10,466	61,638	(28)	61,610

(4) Condensed quarterly consolidated statement of cash flows

(Millions of yen)

	Six months ended September 30, 2021	Six months ended September 30, 2022
Cash flows from operating activities		
Profit before tax	1,715	2,234
Depreciation and amortization	750	936
Decrease (increase) in trade and other receivables	329	616
Decrease (increase) in inventories	3	(24)
Increase (decrease) in trade and other payables	(667)	(1,244)
Other	(304)	232
Subtotal	1,826	2,751
Interest and dividends received	13	0
Interest paid	(28)	(39)
Income taxes paid	(731)	(1,029)
Net cash provided by (used in) operating activities	1,079	1,682
Cash flows from investing activities		
Purchase of property, plant and equipment	(164)	(1,147)
Purchase of intangible assets	(372)	(546)
Payments for loans receivable	—	(760)
Collection of loans receivable	0	110
Purchase of investments	(14)	(106)
Proceeds from purchase of shares of subsidiaries resulting in change in scope of consolidation	—	25
Purchase of shares of subsidiaries resulting in change in scope of consolidation	(3,221)	(19,202)
Other	(20)	132
Net cash provided by (used in) investing activities	(3,792)	(21,494)
Cash flows from financing activities		
Proceeds from short-term borrowings	—	19,330
Repayments of short-term borrowings	(2,622)	(158)
Proceeds from long-term borrowings	1,470	950
Repayments of long-term borrowings	(338)	(570)
Repayments of lease liabilities	(325)	(406)
Proceeds from issuance of shares	—	29,212
Proceeds from exercise of share acquisition rights	108	279
Dividends paid	—	(564)
Other	1	12
Net cash provided by (used in) financing activities	(1,706)	48,086
Net increase (decrease) in cash and cash equivalents	(4,418)	28,273
Cash and cash equivalents at beginning of period	19,898	13,192
Effect of exchange rate changes on cash and cash equivalents	0	0
Cash and cash equivalents at end of period	15,479	41,467

(5) Notes to condensed quarterly consolidated financial statements**Notes on going concern assumption**

Not applicable.

Segment information**(1) Overview of reportable segments**

The Group's reportable segments are components of the Group for which discrete financial information is available, and whose operating results are regularly reviewed by the Board of Directors to make decisions about managerial resources to be allocated to the segments and assess their performances. The Group considers similarities in the nature of the services it provides and has three reportable segments: "Healthcare-Big Data," "Tele-medicine," and "Dispensing Pharmacy Support."

The main businesses and main services included in each reportable segment are as follows.

Reportable segments	Main businesses	Main services
Healthcare-Big Data	Business for industry Business for payers and individuals Business for medical service providers	Development and provision of medical databases (receipts, pharmaceuticals, etc.) and analysis of medical big data
Tele-medicine	Tele-medicine business	Remote image interpretation matching service and ASP service for remote image interpretation system
Dispensing Pharmacy Support	Dispensing pharmacy support business	Development and sales of business systems for dispensing pharmacies

(2) Information about reportable segments

Revenue and operating results by reportable segments of the Group are as follows.

Intersegment revenues are based on negotiated transaction prices, taking into account market prices and production costs. Segment profits are EBITDA (Operating profit + Depreciation and amortization ± Other income/expenses).

Figures for the six months ended September 30, 2021 are the figures after retroactive revision due to the finalization of the provisional accounting treatment for business combinations.

Six months ended September 30, 2021 (from April 1 to September 30, 2021)

(Millions of yen)

	Reportable segments				Adjustments (Note)	Consolidated
	Healthcare- Big Data	Tele-medicine	Dispensing Pharmacy Support	Total		
Revenue						
Revenue from external customers	5,797	2,149	1,603	9,550	—	9,550
Intersegment revenue	31	—	56	88	(88)	—
Total	5,829	2,149	1,659	9,639	(88)	9,550
Segment profit						
EBITDA	1,735	730	163	2,629	(157)	2,472

Note: Adjustments include elimination of intersegment transactions and corporate expenses.

Six months ended September 30, 2022 (from April 1 to September 30, 2022)

(Millions of yen)

	Reportable segments				Adjustments (Note)	Consolidated
	Healthcare- Big Data	Tele-medicine	Dispensing Pharmacy Support	Total		
Revenue						
Revenue from external customers	7,860	2,439	1,759	12,060	–	12,060
Intersegment revenue	42	–	84	126	(126)	–
Total	7,903	2,439	1,843	12,186	(126)	12,060
Segment profit						
EBITDA	2,028	924	192	3,145	(189)	2,956

Note: Adjustments include elimination of intersegment transactions and corporate expenses.

A reconciliation of EBITDA to profit before tax is as follows.

(Millions of yen)

	Six months ended September 30, 2021	Six months ended September 30, 2022
EBITDA	2,472	2,956
Depreciation and amortization	(750)	(936)
Other income	33	203
Other expenses	(21)	(14)
Operating profit	1,733	2,207
Finance income	13	68
Finance costs	(31)	(42)
Profit before tax	1,715	2,234

Significant subsequent events

Not applicable.